ClinicalTrials.gov
ClinicalTrials.gov Menu

Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00836173
Recruitment Status : Withdrawn (Gallium is no longer available for the conduct of this study.)
First Posted : February 4, 2009
Last Update Posted : March 16, 2016
Sponsor:
Collaborator:
Genta Incorporated
Information provided by (Responsible Party):
Scott E Smith, MD, PhD, Loyola University

No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Recruitment Status : Withdrawn
  Actual Primary Completion Date : May 2012
  Actual Study Completion Date : May 2012